Maritoclax and dinaciclib inhibit MCL-1 activity and induce apoptosis in both a MCL-1-dependent and -independent manner

Oncotarget

Volumn 6, Issue 14, 2015, Pages 12668-12681

  Varadarajan, Shankar ^a   Poornima, Paramasivan ^a   Milani, Mateus ^a   Gowda, Krishne ^b   Amin, Shantu ^b   Wang, Hong Gang ^b   Cohen, Gerald M ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Apoptosis; Dinaciclib; Maritoclax; MCL 1; Mitochondria

Indexed keywords

CASPASE 9; COAT PROTEIN COMPLEX I; DINACICLIB; MARITOCLAX; PROTEIN BAK; PROTEIN BAX; PROTEIN INHIBITOR; PROTEIN MCL 1; REACTIVE OXYGEN METABOLITE; UBIQUINOL CYTOCHROME C REDUCTASE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; FUSED HETEROCYCLIC RINGS; MARINOPYRROLE A; MCL1 PROTEIN, HUMAN; PYRIDINIUM DERIVATIVE; PYRROLE DERIVATIVE;

APOPTOSIS; ARTICLE; CELL DEATH; CELL FUNCTION; CELL STRUCTURE; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENCY; ELECTRON TRANSPORT; HUMAN; HUMAN CELL; LUNG CANCER CELL LINE; MITOCHONDRION; PROTEIN FUNCTION; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; FLOW CYTOMETRY; GENE SILENCING; TUMOR CELL LINE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; BRIDGED BICYCLO COMPOUNDS, HETEROCYCLIC; CELL LINE, TUMOR; FLOW CYTOMETRY; GENE KNOCKDOWN TECHNIQUES; HUMANS; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; PYRIDINIUM COMPOUNDS; PYRROLES;

EID: 84930017959     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3706     Document Type: Article

References (48)

1. Hanahan D, Weinberg RA. Hallmarks of Cancer: The Next Generation. Cell 2011; 144:646-674.
2. Decaudin D, Marzo I, Brenner C, Kroemer G. Mitochondria in chemotherapy-induced apoptosis: a prospective novel target of cancer therapy. Int J Oncol 1998;12:141-152.
3. Green DR, Kroemer G. The pathophysiology of mitochondrial cell death. Science 2004;305:626-629.
4. Lessene G, Czabotar PE, Colman PM. BCL-2 family antagonists for cancer therapy. Nat Rev Drug Discov 2008;7:989-1000.
5. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, Joseph MK, Kitada S, Korsmeyer SJ, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005;435:677-681.
6. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, Johnson EF, Marsh KC, Mitten MJ, Nimmer P, Roberts L, Tahir SK, Xiao Y, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008;68:3421-3428.
7. van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE, Willis SN, Scott CL, Day CL, Cory S, Adams JM, Roberts AW, Huang DC. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006;10:389-399.
8. Vogler M, Dinsdale D, Dyer MJS, Cohen GM. Bcl-2 inhibitors: small molecules with a big impact on cancer therapy. Cell Death Differ 2009;16:360-367.
9. Vogler M, Weber K, Dinsdale D, Schmitz I, Schulze-Osthoff K, Dyer MJS, Cohen GM. Different forms of cell death induced by putative BCL2 inhibitors. Cell Death Differ 2009;16:1030-1039.
10. Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, Dayton BD, Ding H, Enschede SH, Fairbrother WJ, Huang DCS, Hymowitz SG, Jin S, Khaw SL, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013;19:202-208.
11. Vogler M, Dinsdale D, Dyer MJS, Cohen GM. ABT-199 selectively inhibits BCL2 but not BCL2L1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not platelets. Br J Haematol 2013;163:139-142.
12. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, McHenry KT, Pinchback RM, Ligon AH et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010;463: 899-905.
13. Dai Y, Grant S. Targeting multiple arms of the apoptotic regulatory machinery. Cancer Res 2007;67:2908-2911.
14. Gores GJ, Kaufmann SH. Selectively targeting Mcl-1 for the treatment of acute myelogenous leukemia and solid tumors. Genes Dev 2012;26:305-311.
15. Zhang H, Guttikonda S, Roberts L, Uziel T, Semizarov D, Elmore SW, Leverson JD, Lam LT. Mcl-1 is critical for survival in a subgroup of non-small-cell lung cancer cell lines. Oncogene 2010;1-6.
16. Varadarajan S, Vogler M, Butterworth M, Dinsdale D, Walensky LD, Cohen GM. Evaluation and critical assessment of putative MCL-1 inhibitors. Cell Death Differ 2013;20:1475-1484.
17. Hwang JJ, Kuruvilla J, Mendelson D, Pishvaian MJ, Deeken JF, Siu LL, Berger MS, Vallet J, Marshall JL. Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma. Clin Cancer Res 2010;16:4038-4045.
18. Joseph TL, Lane DP, Verma CS. Stapled BH3 peptides against MCL-1: mechanism and design using atomistic simulations. PLoS ONE 2012;7:e43985.
19. Wei G, Margolin AA, Haery L, Brown E, Cucolo L, Julian B, Shehata S, Kung AL, Beroukhim R, Golub TR. Chemical Genomics Identifies Small-Molecule MCL1 Repressors and BCL-xL as a Predictor of MCL1 Dependency. Cancer Cell 2012;21:547-562.
20. Cohen NA, Stewart ML, Gavathiotis E, Tepper JL, Bruekner SR, Koss B, Opferman JT, Walensky LD. A competitive stapled peptide screen identifies a selective small molecule that overcomes MCL-1-dependent leukemia cell survival. Chem Biol 2012;19:1175-1186.
21. Inoue S, Walewska R, Dyer MJS, Cohen GM. Downregulation of Mcl-1 potentiates HDACi-mediated apoptosis in leukemic cells. Leukemia 2008;22:819-825.
22. Kapuria V, Peterson LF, Fang D, Bornmann WG, Talpaz M, Donato NJ. Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis. Cancer Res 2010;70:9265-9276.
23. Schwickart M, Huang X, Lill JR, Liu J, Ferrando R, French DM, Maecker H, O'Rourke K, Bazan F, Eastham-Anderson J, Yue P, Dornan D, Huang DCS et al. Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature 2010;463:103-107.
24. Doi K, Liu Q, Gowda K, Barth BM, Claxton D, Amin S, Loughran TP, Wang H-G. Maritoclax induces apoptosis in acute myeloid leukemia cells with elevated Mcl-1 expression. Cancer Biol Ther 2014;15:1077-1086.
25. Pandey MK, Gowda K, Doi K, Sharma AK, Wang H-G, Amin S. Proteasomal degradation of Mcl-1 by maritoclax induces apoptosis and enhances the efficacy of ABT-737 in melanoma cells. PLoS ONE 2013;8:e78570.
26. Doi K, Li R, Sung SS, Wu H, Liu Y, Manieri W, Krishnegowda G, Awwad A, Dewey A, Liu X, Amin S, Cheng C, Qin Y, et al. Discovery of Marinopyrrole A (Maritoclax) as a Selective Mcl-1 Antagonist that Overcomes ABT-737 Resistance by Binding to and Targeting Mcl-1 for Proteasomal Degradation. J Biol Chem 2012;287:10224-10235.
27. Kumar SK, LaPlant B, Chng WJ, Zonder J, Callander N, Fonseca R, Fruth B, Roy V, Erlichman C, Stewart AK. Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single agent activity in patients with relapsed multiple myeloma. Blood 2014;121:329.
28. Feldmann G, Mishra A, Bisht S, Karikari C, Garrido-Laguna I, Rasheed Z, Ottenhof NA, Dadon T, Alvarez H, Fendrich V, Rajeshkumar NV, Matsui W, et al. Cyclindependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models. Cancer Biol Ther 2011;12:598-609.
29. Booher RN, Hatch H, Dolinski BM, Nguyen T, Harmonay L, Al-Assaad A-S, Ayers M, Nebozhyn M, Loboda A, Hirsch HA, Zhang T, Shi B, Merkel CE, et al. MCL1 and BCL-xL levels in solid tumors are predictive of dinaciclibinduced apoptosis. PLoS ONE 2014;9:e108371.
30. Parry D, Guzi T, Shanahan F, Davis N, Prabhavalkar D, Wiswell D, Seghezzi W, Paruch K, Dwyer MP, Doll R, Nomeir A, Windsor W, Fischmann T, et al. Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor. Mol Cancer Ther 2010;9:2344-2353.
31. Cheng C, Pan L, Chen Y, Song H, Qin Y, Li R. Total synthesis of (+/-)-marinopyrrole A and its library as potential antibiotic and anticancer agents. J Comb Chem 2010;12:541-547.
32. Perciavalle RM, Stewart DP, Koss B, Lynch J, Milasta S, Bathina M, Temirov J, Cleland MM, Pelletier S, Schuetz JD, Youle RJ, Green DR, Opferman JT. Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples mitochondrial fusion to respiration. Nature Cell Biol 2012;14:575-583.
33. Varadarajan S, Butterworth M, Wei J, Pellecchia M, Dinsdale D, Cohen GM. Sabutoclax (BI97C1) and BI112D1, putative inhibitors of MCL-1, induce mitochondrial fragmentation either upstream of or independent of apoptosis. Neoplasia 2013;15:568-578.
34. Chen Q, Vazquez EJ, Moghaddas S, Hoppel CL, Lesnefsky EJ. Production of reactive oxygen species by mitochondria: central role of complex III. J Biol Chem 2003; 278: 36027-36031.
35. Norton M, Ng AC-H, Baird S, Dumoulin A, Shutt T, Mah N, Andrade-Navarro MA, McBride H, Screaton RA. ROMO1 Is an Essential Redox-Dependent Regulator of Mitochondrial Dynamics. Sci Signal 2014; 7:ra10.
36. Reily C, Mitchell T, Chacko BK, Benavides G, Murphy MP, Darley-Usmar V. Mitochondrially targeted compounds and their impact on cellular bioenergetics. Redox Biol 2013;1:86-93.
37. Criscitiello C, Viale G, Esposito A, Curigliano G. Dinaciclib for the treatment of breast cancer. Expert Opin Investig Drugs 2014;23:1305-1312.
38. Fabre C, Gobbi M, Ezzili C, Zoubir M, Sablin M-P, Small K, Im E, Shinwari N, Zhang D, Zhou, H, Tourneau CL. Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients. Cancer Chemother Pharmacol 2014;74:1057-1064.
39. Johnson AJ, Yeh Y-Y, Smith LL, Wagner AJ, Hessler J, Gupta S, Flynn J, Zhang X, Bannerji R, Grever MR, Byrd JC. The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells. Leukemia 2012;26:2554-2557.
40. Stephenson JJ, Nemunaitis J, Joy AA, Martin JC, Jou Y-M, Zhang D, Statkevich P, Yao S-L, Zhu Y, Zhou H, Small K, Bannerji R, Edelman MJ. Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer. Lung Cancer 2014;83:219-223.
41. Mita MM, Joy AA, Mita A, Sankhala K, Jou Y-M, Zhang D, Statkevich P, Zhu Y, Yao S-L, Small K, Bannerji R, Shapiro CL. Randomized phase II trial of the cyclindependent kinase inhibitor dinaciclib (MK-7965) versus capecitabine in patients with advanced breast cancer. Clin Breast Cancer 2014;14:169-176.
42. Several clinical trials, using dinaciclib, available from: http:/clinicaltrials.gov.
43. Eichhorn JM, Alford SE, Hughes CC, Fenical W, Chambers TC. Purported Mcl-1 inhibitor marinopyrrole A fails to show selective cytotoxicity for Mcl-1-dependent cell lines. Cell Death Dis 2013;4:e880.
44. Perciavalle RM, Opferman JT. Delving deeper: MCL-1's contributions to normal and cancer biology. Trends Cell Biol 2013;23:22-29.
45. Huang C-R, Yang-Yen H-F. The fast-mobility isoform of mouse Mcl-1 is a mitochondrial matrix-localized protein with attenuated anti-apoptotic activity. FEBS Lett 2010;584:3323-3330.
46. Warr MR, Mills JR, Nguyen M, Lemaire-Ewing S, Baardsnes J, Sun KLW, Malina A, Young JC, Jeyaraju DV, O-Connor-McCourt M, Pellegrini L, Pelletier J, Shore GC. Mitochondrion-dependent N-terminal Processing of Outer Membrane Mcl-1 Protein Removes an Essential Mule/Lasu1 Protein-binding Site. J Biol Chem 2011;286:25098-250107.
47. Varadarajan S, Bampton ETW, Smalley JL, Tanaka K, Caves RE, Butterworth M, Wei K, Pellecchia M, Mitcheson J, Gant TW, Dinsdale D, Cohen GM. A novel cellular stress response characterised by a rapid reorganisation of membranes of the endoplasmic reticulum. Cell Death Differ 2012;19:1896-1907.
48. Vogler M, Dinsdale D, Sun X-M, Young KW, Butterworth M, Nicotera P, Dyer MJS, Cohen GM. A novel paradigm for rapid ABT-737-induced apoptosis involving outer mitochondrial membrane rupture in primary leukemia and lymphoma cells. Cell Death Differ 2008; 15:820-830.